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Introduction. Chronic liver diseases (CLD) are an important cause of morbidity and mortality 
in general population. The aim of this study was to analyze potential differences between patients 
with CLD and healthy control group, and to estimate the severity of CLD by using simple 
questionnaires: general health questionnaire (GHQ-12) and chronic liver disease questionnaire (CLDQ). 
Methods. A cross-sectional pilot study was performed in Zemun Clinical Hospital during 
years 2014 and 2015. Sixty participants were divided into 4 groups (15 per group): chronic alcoholic 
hepatitis, other chronic hepatitis, liver cirrhosis, and healthy control group. Entire study population 
chose one of four offered answers of structured questionnaires GHQ-12 and CLDQ, based on which 
mean model of end-stage liver disease (MELD) and Child-Turcotte-Pugh (CTP) scores were calculated.  
Results. Mean GHQ12 and CLDQ scores were 10.5 and 5.21 ± 1.11 respectively. Regarding 
certain CLDQ domain scores, a significant difference between alcoholic and non-alcoholic hepatitis 
groups in the worry domain was observed. Mean MELD score was 7.42 ± 2.89 and did not differ 
between chronic hepatitis groups, while mean CTP score was 5.73 ± 0.88. A statistically significant 
correlation was observed between GHQ12 and CLDQ scores (ρ = -0.404, p < 0.01), but not between 
subjective and objective scores. 
Conclusions. Mean GHQ12 and CLDQ scores pointed out to general psychological no-distress 
condition of the studied participants, as well as scarcely expressed CLD-specific complaints. Mean 
MELD and CTP scores indicated stable chronic liver diseases, with low three-month mortality rates 
in the cases of chronic hepatitis, as well as determination to Child A group in the case of liver cirrhosis.  
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INTRODUCTION 
Chronic hepatitis is clinical syndrome of hetero-
geneous etiology, defined as liver inflammation, 
continuously lasting for six months. There are 
several causes of chronic hepatitis: hepatitis C virus 
(HCV) and hepatitis B virus (HBV) infection, 
medicamentous hepatitis, alcoholic and non-alcoholic 
steatohepatitis (NASH) [1].  
Quality of life (QoL) is an individual perception 
of person’s own life in the context of cultural and 
socially accepted value system, regarding the goals, 
standards, expectations and concerns, according to 
WHOQOL [2]. QoL measurement instruments can 
be classified into: a) general or generic, b) disease-
specific, and c) instruments measuring economic 
aspects of health and analyzing medical decision 
making (utility measures)[3]. Disease-specific question-
naires focus on individual perception of a patient 
[3]. 
The General Health Questionnaire (GHQ-12) 
is a general type questionnaire intended to assess 
current mental status of the patients in a variety of 
illnesses, including liver disease; it also represents 
a subjective assessment of the effects of the therapy 
[4]. 
Specific questionnaires are used for a 
particular disease, such as questionnaire for chronic 
liver disease (CLDQ) [5]. CLDQ is clinically more 
likely to be applicable, because it is significantly 
shorter and easier to understand than other similar 
questionnaires [6]. Although worse CLDQ score 
indicates greater severity to the liver disease, it 
does not have the ability to discriminate precisely 
the earlier from advanced stages of the liver disease 
[3]. CLDQ was authorized by Younussi et al. [7] 
and was adapted for use within the patients in 
Serbia [8]. Now, this questionnaire is widely used 
among clinicians.  
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This study was performed in order to analyze 
potential differences between patients with CLD 
and healthy control, also to estimate the severity of 
CLD by using the scores obtained by GHQ12 and 
CLDQ questionnaires. 
MATERIALS AND METHODS 
A cross-sectional pilot study was performed 
in the Hepatology outpatient department of Zemun 
Clinical Hospital (ZCH). After the approval of the 
Ethics Committee of ZCH, the patients voluntarily 
agreed to participate in the study. The methodology 
and objectives of the study were clearly explained 
to the participating respondents, and they signed 
informed consents. Respondents were recruited by 
the time of arrival to outpatient clinic, and clustered 
into subgroups according to the diagnosis of liver 
disease. After meeting the quota of 15 participants 
per group, a total of 60, the recruitment of res-
pondents for this pilot study was closed. All 60 
participants were examined, divided into four 
groups (15 per group): first group included outpatients 
suffering from chronic alcoholic hepatitis, the 
second group was formed of outpatients with other 
chronic liver diseases (viral-HBV and HCV, non-
alcoholic and medicamentous hepatitis), the third 
group consisted of outpatients with cirrhosis, while 
the fourth group was the healthy control group. 
CLD was diagnosed by histological criteria, or by 
the levels of serum aminotransferases that were  
1.5 times higher than the upper limit of normal 
reference interval values for the duration of more 
than six months. Viral etiology of chronic liver 
disease has been confirmed by ELISA HBsAg, or 
ELISA anti HCV tests in the Transfusion Laboratory 
of ZCH. The diagnosis of cirrhosis was based on 
patients’ disease history, clinical, physical and 
laboratory parameters, abdominal ultrasound scan, 
and histological criteria [9]. The inclusion criterion 
was CLD, while the exclusion criteria were: first 
check-up of patients with chronic hepatitis after the 
hospitalization, liver malignancies, cardiac cirrhosis, 
decompensated cirrhosis, or acute complications of 
liver cirrhosis of any etiology (variceal bleeding, 
hepatic encephalopathy, acute liver failure). Patients 
with transplanted liver or any other organ, and with 
HIV co-infection, were excluded from the study.  
In our study, we have used GHQ-12 as generic 
questionnaire, and CLDQ as disease-specific type 
of questionnaire. All participants were informed 
with a structured questionnaire (GHQ12 and CLDQ), 
and then we explained them how to fill the 
questionnaires (choosing one of the four answers 
offered). The data analysis was based on the rank 
transformation of chosen answers into numerical 
values with rising tendency- a standard (Likert) 
score [values 0, 1, 2 and 3] [10]. Maximal value of 
the standard score is 36. A higher score indicates a 
higher degree of disturbance of the general health 
status [4, 10]. Ranking within groups is presented 
in Table 1.  
Table 1 
General health questionnaire (GHQ12) scoring system 
GHQ12 score Group Description 
0-15 1 - normal Without distress 
16-25 2 - minor Mild distress 
≥ 25 3 - major Severe distress 
 
CLDQ consists of 29 questions, with 7 struc-
tured answers (1 - all the time present; 7 - never 
present). The greater the score, the number of an-
noyances is smaller, and vice versa. Score is 
composed of 6 domains, which have a different 
number of questions related to: abdominal symptoms 
(3 questions; the order of 1, 5, 17), fatigue  
(5 questions; the order of 2, 4, 8, 11, 13), systemic 
symptoms (5 questions; the order of 3, 6, 21, 23, 
27), the activity (3 questions; the order of 7, 9, 14), 
emotional functioning (8 questions; the order of 10, 
12, 15, 16, 19, 20, 24, 26), as well as concerns  
(5 questions; the order of 18, 22, 25, 28, 29). The 
average score for each domain is equal to the sum 
of ranks for all issues related to this area, divided 
by the number of questions. Total CLDQ score is 
equal to the sum of scores of a particular domain 
divided by the total number of questions. Popovic 
et al. [8] have validated the questionnaire for our 
patients.  
To assess the liver disease severity and 
survival rate, we used the mean model of end-stage 
liver disease (MELD) in the case of chronic hepatitis 
[11] and Child-Turcotte-Pugh score (CTP) for the 
liver cirrhosis [12]. Calculation of MELD score 
requires determination of serum bilirubin and cre-
atinine levels, as well as International Normalized 
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Ratio for Prothrombin Time (INR). MELD score 
was calculated using the following formula: 
MELD = 3.78 × ln [bilirubin] + 11.2 × ln [INR] + 
9.57 × ln [creatinine] + 6.43 × etiology 
(0: holestatic or alcoholic, 1 - others) 
Calculated MELD score was used to predict 
three-month mortality rates, as follows: <9 (1-9%), 
10-19 (6%), 20-29 (19, 6%), 30-39 (52, 6%), ≥40 
(71, 3%) [11]. Values of the variables needed to 
calculate the CTP score [12] are presented in Table 2. 
On the morning after the questionnaires fulfilling, 
blood samples were taken from participants for 
measurement of creatinine, total bilirubin, albumin, 
prothrombine time, and determination of INR. 
Serum creatinine was measured by Jaffe reaction, 
on the IL 650 analyzer (Instrumentation Laboratory, 
USA), expressed in µmol/L. The reference values 
are between 44 and 133 µmol/L. Total bilirubin 
was determined by diazo method, expressed in 
µmol/L, with the reference values from 4.96 to 
23.36 µmol/L. Serum albumin levels were determined 
by bromocresol method, on the same analyzer, 
expressed in g/L, with the reference values 35-55 g/L. 
Prothrombin time was determined by the IL analyzer 
 
ACL Elite Pro (Instrumentation Laboratory, USA), 
expressed in seconds. INR is the ratio of the 
participants’ and healthy witness’ prothrombin time 
and it is expressed as a decimal number. The 
normal value is 1.00. MELD score evolved from  
3 months-mortality prediction score in TIPS 
patients to scoring system for assessing the severity 
of chronic liver diseases. Nowadays, it has a role in 
priority recruitment of liver transplant recipients by 
Eutransplant and UNOS. Thus, MELD has been 
recognized as a major contribution to the daily 
practice of hepatology [11]. To overcome some 
limitations, an improvement could be made in the 
future (for example, introduction of sodium and 
renal function analyses). 
Demographic parameters (gender, age, marital 
and educational status, occupation) and medical 
history (risk factors for liver disease, HBV vaccination, 
family burden, the duration of liver disease, 
number of hospitalizations due to a liver disease, 
and number of cirrhosis decompensations) were 
analyzed, as well. Finally, the participants were 
asked about the overall subjective feeling within 
the past two months, with structured answers 
analyzed in Table 3. 
Table 2 
Variables and calculating the Child-Turcotte-Pugh (CTP) score (sum of numerical values for 5 variables) 
Variable 1 point 2 points 3 points 
Total bilirubin (µmol/L)  < 34 34-50 > 50 
Serum albumin (g/L) > 35 28-35 < 28 
PT - INR < 1.7 1.71-2.30 > 2.30 
Ascites none mild moderate to expressed
Encephalopathy none I-II degree (or suppressed by medicine) 
III-IV degree 
(or refractory) 
 PT-INR - Prothrombin Time - International Normalized Ratio 
Table 3 
Value of Child-Turcotte-Pugh (CTP) score, class affiliation, and survival 
Scores Class One-year survival Two-year survival 
5-6 A 100% 85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
 
STATISTICAL ANALYSIS 
In the data analysis, we used measures of 
central tendency (median and mean values), and 
variability measures (standard deviation and coefficient 
of variation) were used. To assess the normality of 
the data distribution, Kolmogorov-Smirnov test 
was used. Also, Spearman’s rank correlation test 
for potential nonparametric correlations was used. 
As far as potentially significant differences, chi-
square test was used for categorical data, and 
nonparametric Mann-Whitney test to examine the 
differences between two groups with continuous 
variables that do not follow normal distribution. 
For the three group comparison, we used parametric 
and non-parametric-factor analysis of variance 
(ANOVA / LSD test posthoc- / and Kruskal-Wallis 
test). P values < 0.05 were considered as sig-
nificant. Statistical package SPSS for Windows 
17.0 (SPSS Inc., Chicago, Illinois) was used.  
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RESULTS 
The study included 60 participants with the 
mean age of 60 ± 11 (26-84) years, (Table 4). Of 
all participants, 38 (63%) were male, and the 
frequency distribution significantly differed between 
groups formed according to gender (χ2 = 18.660,  
p < 0.01) (Table 4). The average duration of liver 
disease significantly differed among the groups  
(χ2 = 10, 990 p < 0.01) (Table 4). GHQ12 average 
score was 10.5 (2-26), with no significant dif-
ferences among the examined groups (Table 4). 
Average MELD score for the participants with 
chronic hepatitis was 7.42 ± 2.89 (6.00-21.00), and 
no significant differences among subgroups with 
chronic hepatitis were observed (Table 4). Average 
CTP score for the group with compensated cirrhosis 
was 5.73 ± 0.88 (5.00-8.00) (Table 4). 
Table 4 
Summarized data by the groups 
Variable Group 1 (n = 15) 
Group 2 
(n = 15) 
Group 3 
(n = 15) 
Group 4 
(n = 15) 
Gender [♂ (%)] 14 (93) 6 (40) 13 (87) 5 (33) 
Age 
[X±SD (min–max)] 
56±12 
(38-75) 
59±11 
(35-84) 
65±6 
(56-74) 
60±15 
(26-70) 
Duration of the liver 
disease 
[Med (min–max)] 
1 (1-7) 6 (1-22) 3 (1-16)  
GHQ12 score 
[Med (min–max)] 10 (2-20) 11 (7-26) 11 (5-22) 9 (3-19) 
Normal 14 (93) 12 (80) 10 (67) 13 (87) 
Minor 1 (7) 2 (13) 5 (33) 2 (13) GHQ12 [n (%)] Major 0 1 (7) 0 0 
AS 5.49±0.96 (3.00-7.00) 
4.64±1.59 
(2.33-7.00) 
5.78±1.15 
(4.00-7.00) 
4.87±1.57 
(2.67-7.00) 
F 5.25±1.13 (3.00-6.80) 
4.61±1.44 
(1.00-7.00) 
5.16±1.34 
(2.80-6.60) 
4.87±1.18 
(2.80-7.00) 
SS 5.53±1.15 (3.00-7.00) 
5.32±1.27 
(2.00-7.00) 
5.68±1.06 
(3.20-7.00) 
5.15±1.30 
(2.80-7.00) 
AC 5.87±1.12 (3.33-7.00) 
5.04±1.60 
(1.00-7.00) 
5.95±0.97 
(4.33-7.00) 
5.44±1.56 
(2.33-7.00) 
EF 5.34±1.02 (3.25-6.88) 
4.63±1.29 
(1.88-6.75) 
4.99±1.09 
(2.88-6.38) 
5.02±1.23 
(2.88-6.75) 
W 5.36±0.99 (3.60-7.00) 
4.23±1.76 
(1.00-7.00) 
5.11±1.74 
(1.00-7.00) 
5.87±1.14 
(3.40-7.00) 
CLDQ 
[X±SD 
(min–
max)] 
Ʃ 5.47±0.86 (3.61-6.71) 
4.75±1.35 
(1.53-6.93) 
5.44±1.05 
(3.48-6.63) 
5.20±1.06 
(3.20-6.48) 
MELD score 
[Med (min–max)] 7 (6-9) 7 (6-21) / / 
CTP score 
[Med (min–max)] / / 6 (5-8) / 
better 1 (7) 3 (20) 3 (20) 6 (40) 
the same 10 (67) 10 (67) 11 (73) 5 (33) Feeling [n (%)] worse 4 (26) 2 (13) 1 (7) 4 (27) 
AS - abdominal symptoms; F- fatigue; SS - systemic symptoms; AC - activity; EF - emotional functions; W - worry; Ʃ - total, GHQ-12 - general 
health questionnaire; CLDQ - chronic liver disease questionnaire; MELD - model of end-stage liver disease; CTP –Child-Turcotte-Pugh score. 
 
Considering the occupation of participants, 
most of them were mechanic technicians - 23 (38%), 
economists -8 (13%), traders -5 (8%), logistician  
-4 (7%). Professions related to medicine, health, 
education and housewives, referred to -3 (5%) of 
participants, while automechanic, agricultural and 
catering professions belonged to -2 (3%) of the 
participants, and other professions to the remaining 
-5 (9%) participants.  
Within our cohort, 37 (62%) of participants 
consumed daily or periodically alcoholic beverages. 
Fifteen of them (47%) used alcohol up to 25 years. 
Consumption of different alcoholic beverages 
referred to 20 (54%) participants of this study, who 
preferentially used the following types of drinks: 
17 (46%) used strong alcoholic beverages, 15 (40%) 
beer, and 5 (14%) wine. Maximum daily con-
sumption of strong alcoholic beverages was 1l, 3l of 
wine and 3.5l of beer. None of them abused drugs 
intravenously, while 5 (8%) of them had tattoos 
(four of them belonged to the subgroup of patients 
with alcoholic hepatitis, and one of them was from 
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the subgroup of patients with non-alcoholic 
(HCV+) hepatitis. Three percent of participants 
were vaccinated against HBV infection. One of 
them was infected with HCV and had chronic 
hepatitis, while the other participant belonged to 
the control group.  
Thirteen participants (76%) had surgical 
procedure in the past (as potential risk to gain 
chronic liver disease due to an infection).  
Liver disease was histologically confirmed in 
4 (9%) patients, a total of 13 (22%) patients were 
hospitalized, and 10 (17%) of participants had some 
of the manifestations of hepatic decompensation.  
The frequency distribution of participants 
according to GHQ12 score modalities is presented 
 
in Table 5, and the total CLDQ and the scores of 
particular domains are presented in Table 6. Fig. 1 
shows the frequency distribution of participants 
divided into groups according to the structured 
answers regarding general subjective emotional 
status for the past two months. There were no 
differences in participants’ frequency distribution 
between GHQ12 score groups and groups formed 
according to structured answers regarding general 
subjective emotional status for the past two months 
(χ2 = 2.627, p > 0.05). Correlation coefficients 
between the scores that assess QoL and clinical 
scores for the estimation of the disease severity are 
shown in Table 7. 
Table 5 
Frequency distribution according to gradation of GHQ12 questionnaire 
Gradation of GHQ12 score n (%) 
Normal 49 (82) 
Minor 10 (17) 
Major 1  
Table 6 
Cumulative CLDQ and scores by the domains in the examined population 
CLDQ Arithmetic mean ± SD Min-Max p 
Abdominal symptoms 5.19±1.39 2.33-7.00 ns 
Fatigue 4.97±1.27 1.00-7.00 ns 
Systemic symptoms 5.42±1.19 2.00-7.00 ns 
Activity 5.58±1.36 1.00-7.00 ns 
Emotional functions 4.99±1.16 1.87-6.87 ns 
Worry 5.14±1.53 1.00-7.00 <0.05* 
Total 5.21±1.11 1.53-6.92 ns 
                                     *- alcoholic hepatitis vs. other hepatitis < 0.05 
Table 7 
Correlation coefficients among scores in the examined population 
Correlation 
coefficients (ρ) 
GHQ12 CLDQ MELD CTP 
GHQ12 /  -0.404** +0.377 +0.024 
CLDQ  -0.404** / -0.060 +0.152 
MELD +0.377 -0.060 / / 
CTP +0.024 +0.152 / / 
** p < 0.01 
GHQ-12 - general health questionnaire; CLDQ - chronic liver disease questionnaire; 
MELD - model of end-stage liver disease; CTP - Child-Turcotte-Pugh score. 
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Figure 1. Frequency distribution of participants according to the two-month subjective feeling. 
DISCUSSION 
The aim of this study was to test the 
application simplicity of offered Qol assessment 
questionnaires developed by ZCH clinicians, and 
then to examine whether subjective assessment of 
respondent’s state corresponds to the objective 
severity of the disease, defined through simple 
objective and easily processed scores for outpatient 
settings (in this study the correlation was not 
registered). Thus, subjective QoL scores correlate 
between groups (fulfilling even one of the two 
offered QoL questionnaires is useful), but the sub-
jective and objective scores do not. The explanation 
may lie in the nature and course of hepatic disease. 
Average MELD score for CLD, or CTP score for 
compensated liver cirrhosis, suggested the presence 
of stable liver disease, in terms of prognosis with a 
low three-month mortality rate for chronic hepatitis 
or belonging to the Child A group for the par-
ticipants with liver cirrhosis with one- and two-year 
survival rate of 100% and 85%, respectively. In 
regard to scores correlation, results show a statistically 
negative correlation between GHQ12 and CLDQ.  
The majority of studies have analyzed viral 
etiology of CLD followed by alcoholic liver disease, 
NASH, holestatic liver disease, autoimmune hepatitis, 
and medicamentous hepatitis [13-15]. There are 
concordant results in other similar studies regarding the 
average age of participants, gender, marital status, 
and educational status [8, 15-17]. Significant pre-
dominance of males in different etiologic groups is 
consistent with the data from literature. Also, our 
results are in orchestra with literature data, and 
indicate higher frequency of males within the group 
of alcoholic liver disease patients. This was not the 
case with the CLD of other etiology, where the 
distribution by gender was significantly more 
uniform compared to the previous studies [16-18]. 
In this study, the duration of CLD was a little 
longer (average 5 years) compared with the data 
from most of the relevant studies [18, 19], although 
the data relating to the length of the disease might 
not be reliable enough, because of the oligo-
symptomatc disease onset. The mean duration of 
the disease was statistically significantly longer in 
patients with non-alcoholic hepatitis compared with 
the alcoholic etiology and patients with liver 
cirrhosis.  
healthy 
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Average QoL score measured by GHQ12 
questionnaire indicates the absence of distress in 
patients with CLD compared with the control 
group and also shows the absence of statistically 
significant intergroup differences. Moreover, an in-
creasing number of patients with “mild” distress 
was a characteristic for the group of patients with 
cirrhosis, but without statistical significance in 
terms of frequency distribution. Our results differ 
from literature data [14]. According to the most 
relevant studies, generic QoL score (mainly assessed 
by SF-36 questionnaire) was significantly lower 
within the patients with CLD compared with 
healthy controls, including the studies of Bondini  
et al. [20], which indicate significantly lower  
SF-36 scores in patients with cholestatic liver 
diseases and viral hepatitis C in comparison with 
the control group. The study of Younossi et al. [21] 
pointed out that the SF36 scores were significantly 
lower in the group of patients with CLD regardless 
of the etiology, compared with healthy subjects. 
Svirtlih et al. [22] showed significantly poorer QoL 
evaluated by SF-12 questionnaire in patients with 
viral hepatitis compared to the control group, with 
no significant differences in terms of QoL regarding 
the etiology of viral hepatitis. 
When the values of QoL scores have been 
compared in other studies, among groups of patients 
suffering from CLD of different etiology, different 
results were shown. Study of Afendy et al. [15] 
shows the lowest scores in the SF-36 questionnaire 
within the group of patients with NASH compared 
with the subjects suffering from alcoholic, viral, 
and chronic cholestatic liver disease. Similar results 
were shown in the studies of Dan et al. [23] where 
they estimated QoL by CLDQ questionnaire in the 
group of patients with NASH and viral hepatitis, 
with registered CLDQ lowest scores in subjects 
with NASH, followed by subjects with chronic 
HCV hepatitis, while the highest score was related 
to the subjects with chronic HBV hepatitis. Study 
of Pavic et al. [24] indicated significantly lower 
SF-16 scores in some questionnaire domains within 
the patients with chronic HCV hepatitis, compared 
with the patients with chronic HBV hepatitis. 
Results of the study of Martin et al. [25] high-
lighted the impact of etiology of CLD on QoL 
scores in earlier stages of disease, while the influence 
of etiology on QoL score gradually disappears as 
the disease progresses to cirrhosis, similarly to the 
studies of Kalaitzakis et al. [26] who examined the 
impact of the etiology of liver cirrhosis on the QoL. 
Comparing the QoL of examined patients, 
using disease-specific questionnaire-CLDQ, we 
observed a significantly lower score in the “worry” 
domain in the group of patients with non-alcoholic 
hepatitis. Scores of other domains CLDQ question-
naire did not significantly differ among the examined 
groups. In contrast to this, the results of the study 
Dan et al. [23] show the existence of significantly 
lower CLDQ scores in all domains except for the 
“worry” domain in patients with NASH compared 
with those suffering from viral hepatitis. Study of 
Parkash et al. [16] has found a significantly lower 
CLDQ score within the group of patients with 
cirrhosis compared with those without cirrhosis. 
Similar results were presented by the Younossi  
et al. [21] and Che et al. [17], similarly to the 
severity of CLD with the MELD score from our 
present study. Majority of published studies 
pointed out a significant correlation between the 
severity of the disease and reduced QoL score, 
assessed by generic CLDQ questionnaires. Study 
of Gotardo et al. [27] found significantly lower 
QoL estimated by SF-36 and CLDQ questionnaires 
in more advanced stages of CLD (MELD score was 
higher than 15 and the CTP-class C) within the 
group of patients who are awaiting liver transplants, 
and they also observed significantly worse scores 
within the patients with chronic HCV hepatitis 
compared with liver diseases of other etiologies.  
The limitation of our study was the small 
number of cases analyzed in some groups. Con-
sidering the fact that this is a pilot study, which 
was supposed to justify the use of the offered QoL 
questionnaires, and objective scores on severity of 
liver disease, a small number of participants entered 
the groups, and the study was limited in terms of 
generalizing the conclusions. 
In conclusion, combining analyzed question-
naires (GHQ12, CLDQ) with clinical objective 
scores might improve diagnostics or timely detect 
disease worsening, enable following the effect of 
applied therapy, and help the analysis of novel 
treatments.The importance of applying QoL question-
naires and objective scores lies in timely detection 
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of worsening the hepatic diseases, but also in 
improving the patient-doctor relationship, which 
can significantly affect the results of the subjective 
scores. 
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Introducere. Bolile cronice hepatice (BCH) sunt o cauză importantă de 
mortalitate şi morbiditate în cadrul populaţiei generale. Obiectivul studiului a fost 
de a analiza diferenţele dintre pacienţii cu BCH şi martori sănătoşi precum şi 
evaluarea severităţii BCH folosind două chestionare- GHQ-12 (General health 
questionnaire 12) şi CLDQ (Chronic liver disease questionnaire).  
Materiale şi metode. A fost realizat un studiu transversal pilot în cadrul 
spitalului Clinic din Zemun în perioada 2014-2015. 60 de participanţi au fost 
împărţiţi în 4 grupuri (câte 15 participanţi în fiecare grup): pacienţi cu hepatită 
cronică alcoolică, pacienţi cu alte hepatite cronice, pacienţi cu ciroză hepatică şi 
15 martori sănătoşi. Pacienţii au completat chestionarele GHQ-12 şi CLDQ şi au 
fost calculate scorurile MELD şi Child-Turcotte-Pugh (CTP).  
Rezultate. Scorurile medii GHQ12 şi CLDQ au fost de10.5 şi respectiv 5.21 
± 1.1. În privinţa anumitor scoruri din cadrul chestionarului CLDQ s-a observant 
o diferenţă semnificativă între pacienţii cu hepatită cronică alcoolică şi cei cu 
hepatită cronică de altă etiologie. Scorul mediu MELD a fost de 7.42 ± 2.89 şi nu a 
fost semnificativ statistic diferit între grupurile cu hepatită. Scorul mediu CTP a 
fost de 5.73 ± 0.88. A fost observată o asociere semnificativă statistic între GHQ12 
şi CLDQ (ρ = -0.404, p < 0.01). 
Concluzii. Combinarea chestionarelor GHQ12 şi CLDQ cu scorurile clinice 
obiective ar putea îmbunătăţi diagnosticul şi detecţia înrăutăţirii bolii precum şi 
îmbunătăţirea urmăririi pacienţilor şi analiza noilor terapii. Importanţa aplicării 
chestionarelor legate de calitatea vieţii precum şi a scorurilor clinice obiective 
este baza detecţiei rapide a înrăutăţirii bolii hepatice dar şi îmbunătăţirea relaţiei 
medic-pacient. 
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